Neuropathic Pain Agents - Pharmacology

1. Which of the following agents used for neuropathic pain is classified as a Schedule V controlled substance by the DEA due to its potential for misuse and induction of euphoria?
   Answer: Pregabalin Pregabalin is classified as a Schedule V controlled substance in the United States due to its recognized potential for abuse and physical dependence. It can produce euphoric effects, particularly at higher-than-prescribed doses, making it a target for misuse. Gabapentin (C) is not federally scheduled, although some states have moved to classify it as a controlled substance due to growing evidence of its misuse. Duloxetine (A) and nortriptyline (B) do not have abuse potential and are not scheduled.
2. A physician is choosing between amitriptyline and nortriptyline for an elderly patient with postherpetic neuralgia. The patient has a history of falls and mild cognitive impairment. Why is nortriptyline generally considered a more favorable choice than amitriptyline in this specific patient population?
   Answer: Nortriptyline is a secondary amine TCA with less potent anticholinergic and antihistaminic effects. Nortriptyline is a secondary amine TCA, whereas amitriptyline is a tertiary amine. Secondary amines (like nortriptyline and desipramine) generally have a lower affinity for muscarinic and H1 histamine receptors compared to tertiary amines. This results in a lower burden of anticholinergic side effects (confusion, constipation, dry mouth) and sedation, which are particularly problematic in elderly patients with cognitive impairment and a risk of falls. (A) is incorrect; TCAs do not work via the α2-δ subunit. (C) is incorrect as both drugs are substrates for CYP2D6. (D) is incorrect; both have long half-lives allowing for once-daily dosing.
3. A patient with fibromyalgia is prescribed pregabalin. After 4 weeks of titration to 150 mg twice daily, the patient reports significant dizziness and somnolence, which is interfering with daily activities. The patient has had a minimal reduction in pain. What is the most appropriate next step in managing this patient's therapy?
   Answer: Reduce the pregabalin dose to 75 mg twice daily and reassess tolerability and efficacy. The patient is experiencing dose-limiting side effects (dizziness, somnolence) with minimal efficacy. The most appropriate step is to reduce the dose to a previously tolerated level or a lower dose to see if the side effects resolve while maintaining some efficacy. Increasing the dose (B) would worsen the side effects. Abruptly stopping pregabalin (A) can cause withdrawal symptoms and is not ideal. Adding another CNS depressant like duloxetine (D) without first addressing the tolerability of the current agent could exacerbate the dizziness and somnolence.
4. The analgesic effects of tricyclic antidepressants (TCAs) in neuropathic pain are thought to be distinct from their antidepressant effects. Which of the following observations best supports this distinction?
   Answer: The onset of analgesia is often more rapid (days to a week) than the onset of antidepressant effects (weeks). When you encounter questions about dual mechanisms of psychoactive drugs, focus on how different therapeutic effects can emerge through distinct pathways and timelines, even from the same medication. The key evidence supporting separate mechanisms for TCA analgesia versus antidepressant effects is the dramatic difference in onset timing. Analgesic effects from TCAs typically appear within days to one week of starting treatment, while antidepressant effects require several weeks to manifest. This temporal separation strongly suggests different underlying mechanisms are responsible for each therapeutic effect. Choice A is incorrect because analgesic doses are actually typically lower than antidepressant doses, not higher. This lower dose requirement further supports the distinct mechanism hypothesis. Choice B reverses the actual mechanisms - both analgesic and antidepressant effects involve multiple neurotransmitter systems, but the analgesic effects are thought to involve enhanced descending pain inhibition through both serotonin and norepinephrine pathways. Choice C is wrong because analgesic activity isn't limited to TCAs with strong antihistaminic properties; many TCAs demonstrate pain relief regardless of their histamine receptor affinity. The rapid onset of analgesia compared to the delayed antidepressant response (choice D) provides the strongest pharmacological evidence that these are genuinely separate therapeutic mechanisms rather than the same process applied to different conditions. Study tip: Remember that when the same drug produces different effects with different timelines or dose requirements, this usually indicates distinct mechanisms of action - a concept that appears frequently in psychopharmacology questions.
5. A patient stabilized on venlafaxine for neuropathic pain is prescribed linezolid for a complicated skin infection. Within 48 hours, the patient develops agitation, diaphoresis, resting tremor, and hyperreflexia. This clinical presentation is most likely caused by a drug interaction leading to what condition?
   Answer: Serotonin syndrome This patient is presenting with classic signs of serotonin syndrome. Venlafaxine is a potent serotonin-norepinephrine reuptake inhibitor (SNRI). Linezolid is an antibiotic that also has reversible, non-selective monoamine oxidase inhibitor (MAOI) properties. The combination of an SNRI and an MAOI dramatically increases the risk of serotonin syndrome by increasing synaptic serotonin levels through two different mechanisms. Neuroleptic malignant syndrome (A) is associated with dopamine antagonists. TCA cardiotoxicity (C) is incorrect as the patient is on an SNRI. Anticholinergic crisis (D) presents with symptoms like flushing, dry skin, mydriasis, and delirium ('hot as a hare, blind as a bat, dry as a bone, red as a beet, mad as a hatter').
6. A 45-year-old male is treated with desipramine for chronic neuropathic back pain. He is also taking paroxetine for major depressive disorder. He presents with confusion, fever, and muscle rigidity. The co-administration of these two agents creates a risk for which of the following?
   Answer: Markedly elevated desipramine levels due to inhibition of its metabolism. When you encounter drug interaction questions involving antidepressants, focus on the cytochrome P450 enzyme system and how different medications can inhibit or induce each other's metabolism. The patient's symptoms—confusion, fever, and muscle rigidity—suggest elevated tricyclic antidepressant levels causing toxicity. Desipramine, a tricyclic antidepressant, is metabolized primarily by CYP2D6. Paroxetine is a potent CYP2D6 inhibitor, meaning it blocks the enzyme responsible for breaking down desipramine. When paroxetine inhibits CYP2D6, desipramine accumulates to toxic levels, producing the neurological and autonomic symptoms described. Answer A correctly identifies this mechanism: paroxetine's inhibition of desipramine metabolism leads to markedly elevated drug levels and toxicity. Answer B is incorrect because while both drugs have anticholinergic effects, the primary concern here isn't additive anticholinergic toxicity but rather elevated desipramine levels from metabolic inhibition. The symptoms described are more consistent with tricyclic toxicity than pure anticholinergic effects. Answer C is wrong because paroxetine inhibits rather than induces CYP2D6. Enzyme induction would decrease desipramine levels and reduce efficacy, which contradicts the patient's toxic presentation. Answer D is incorrect because tyramine reactions occur with MAO inhibitors and tyramine-containing foods, not with this drug combination. Neither paroxetine nor desipramine is an MAO inhibitor. Remember this pattern: SSRIs like paroxetine and fluoxetine are potent CYP2D6 inhibitors and frequently cause clinically significant interactions with tricyclic antidepressants, requiring dose adjustments or alternative medications.
7. A patient with painful diabetic neuropathy and comorbid hypertension is managed with lisinopril and hydrochlorothiazide. The physician adds venlafaxine for the neuropathy. Which of the following parameters is most important to monitor after initiating venlafaxine in this patient?
   Answer: Blood pressure Venlafaxine, an SNRI, can cause a dose-dependent increase in blood pressure due to its inhibition of norepinephrine reuptake. In a patient with pre-existing hypertension, it is crucial to monitor blood pressure closely after initiation and with each dose increase. While SNRIs can rarely cause hyponatremia (D) or hepatotoxicity (C), and renal function (A) is always good to monitor, the most common and predictable adverse effect related to the patient's comorbidity is an elevation in blood pressure.
8. A patient with chemotherapy-induced peripheral neuropathy has failed a trial of gabapentin due to lack of efficacy. A decision is made to switch to duloxetine. Which of the following represents a key counseling point specific to initiating duloxetine that differs significantly from counseling for gabapentin?
   Answer: The medication should be tapered slowly upon discontinuation to avoid a withdrawal syndrome. Both SNRIs (like duloxetine) and gabapentinoids can cause withdrawal symptoms if stopped abruptly, but the discontinuation syndrome with SNRIs is often more pronounced and well-characterized, featuring symptoms like dizziness, nausea, anxiety, and 'brain zaps'. This makes counseling on gradual tapering particularly critical for duloxetine. Peripheral edema (B) is more characteristic of gabapentinoids. A delayed onset of action (C) is common to both classes of drugs. The absorption of duloxetine is delayed by food but the total amount absorbed is not significantly affected (D), and this is not a major clinical counseling point compared to discontinuation.
9. Based on the patient's renal function, which medication adjustment is the most critical and evidence-based recommendation?
   Answer: Initiate gabapentin at a significantly reduced dose and with an extended dosing interval. Gabapentin is almost exclusively eliminated unchanged by the kidneys. In a patient with an eGFR of 25 mL/min (Stage 4 CKD), the dose must be significantly reduced and the interval extended to prevent toxic accumulation and severe CNS side effects. While amitriptyline is hepatically metabolized (A), its active metabolites can accumulate in renal failure, so caution is still warranted. Duloxetine (C) is generally not recommended for patients with an eGFR < 30 mL/min, so avoiding it is a valid consideration, but the most critical adjustment among the choices relates to gabapentinoids. Initiating pregabalin at a standard dose (D) is incorrect; like gabapentin, it requires dose reduction based on creatinine clearance.
10. A patient is being counseled on initiating therapy with gabapentin for neuropathic pain. Which statement accurately reflects the titration schedule and rationale for this medication?
    Answer: The dose should be started low and titrated up slowly over days to weeks primarily to improve patient tolerability. Gabapentin must be initiated at a low dose (e.g., 100-300 mg) and titrated up gradually. The primary reason for this slow titration is to minimize CNS side effects, such as somnolence, dizziness, and ataxia, which are common at the beginning of therapy and can lead to non-adherence. A loading dose (A) would cause intolerable side effects. Gabapentin has a relatively short half-life (5-7 hours), requiring multiple daily doses (typically TID) (C). It does not induce its own metabolism (D).
11. While both TCAs and SNRIs inhibit the reuptake of norepinephrine, a key mechanistic distinction of TCAs that contributes significantly to their adverse effect profile but not their primary analgesic effect is their additional action as...
    Answer: antagonists at various receptors, including muscarinic, histaminic, and adrenergic. A major difference between TCAs and SNRIs is that TCAs are 'dirtier' drugs, meaning they interact with many receptor types beyond the norepinephrine and serotonin transporters. Their antagonism of muscarinic cholinergic receptors (causing dry mouth, constipation), H1 histamine receptors (causing sedation, weight gain), and alpha-1 adrenergic receptors (causing orthostatic hypotension) accounts for a large portion of their side-effect burden. SNRIs are much more selective for the reuptake transporters and have minimal affinity for these other receptors, giving them a more favorable side-effect profile.
12. A patient with diabetic neuropathy and comorbid anxiety is being considered for treatment. Which of the following agents offers an evidence-based benefit for both conditions through a single mechanism of action?
    Answer: Venlafaxine, by inhibiting the reuptake of serotonin and norepinephrine. When you encounter questions about dual-indication medications, focus on identifying drugs with well-established mechanisms that address both conditions through the same pathway. This tests your understanding of how pharmacological mechanisms can provide therapeutic benefits across different disease states. Venlafaxine (A) is correct because it's a serotonin-norepinephrine reuptake inhibitor (SNRI) with robust evidence for treating both diabetic neuropathy and anxiety through this single mechanism. The enhanced norepinephrine signaling modulates descending pain pathways to reduce neuropathic pain, while increased serotonin and norepinephrine availability treats anxiety. This dual benefit through one mechanism makes it an ideal choice for comorbid conditions. Pregabalin (B) is wrong because while it does treat both conditions effectively, it doesn't reduce norepinephrine release—it actually blocks voltage-gated calcium channels to decrease excitatory neurotransmitter release, including glutamate. The mechanism described is inaccurate. Amitriptyline (C) is incorrect because although it can help both conditions, it works through multiple mechanisms (not a single one as the question specifies). Its benefits come from various actions including norepinephrine reuptake inhibition, sodium channel blockade, and anticholinergic effects—not just the two mechanisms listed. Gabapentin (D) is wrong on multiple levels. While it treats neuropathic pain, it has limited evidence for anxiety disorders. Additionally, it doesn't directly agonize GABA-B receptors—it binds to voltage-gated calcium channel subunits. Remember: SNRIs like venlafaxine and duloxetine are your go-to dual-indication drugs for neuropathic pain plus mood/anxiety disorders. Focus on learning drugs with clear, single mechanisms that provide multiple therapeutic benefits.
13. The analgesic effect of duloxetine in neuropathic pain is primarily mediated by its ability to potentiate which of the following neurotransmitter systems in the central nervous system?
    Answer: Noradrenergic and serotonergic descending inhibitory pain pathways. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI). Its analgesic effect is believed to stem from its ability to block the reuptake of both serotonin (5-HT) and norepinephrine (NE) in the synaptic cleft. This action enhances the activity of the descending inhibitory pain pathways that originate in the brainstem and project to the spinal cord, thereby dampening the transmission of pain signals. The other options describe mechanisms of different drug classes or are not the primary analgesic mechanism for SNRIs.
14. A patient with postherpetic neuralgia experiences partial relief with a maximum tolerated dose of pregabalin. The physician plans to add a second agent with a complementary mechanism of action. Which of the following describes the primary molecular action of pregabalin that a new agent should complement?
    Answer: Binding to the α2-δ subunit of voltage-gated calcium channels, reducing neurotransmitter release. Pregabalin's primary mechanism is binding to the α2-δ subunit of presynaptic N-type voltage-gated calcium channels. This reduces calcium influx, which in turn decreases the release of excitatory neurotransmitters like glutamate and substance P. To complement this presynaptic inhibitory mechanism, one might add an agent that works postsynaptically or modulates descending inhibitory pathways, like an SNRI (A) or TCA (which also has sodium channel blocking properties, B). (D) describes the mechanism of agents like ketamine, not the primary neuropathic pain agents in this category.
15. A patient taking high-dose venlafaxine for neuropathic pain decides to stop the medication abruptly because they feel better. Two days later, they call the clinic complaining of intense dizziness, anxiety, insomnia, and a sensation of 'electric shocks' in their head. This syndrome is best explained by which neuropharmacological concept?
    Answer: Acute withdrawal due to the medication's short elimination half-life. When you encounter questions about sudden medication discontinuation followed by rapid onset of symptoms, think about discontinuation syndrome and the pharmacokinetic properties that influence its severity. Venlafaxine has a notably short elimination half-life of approximately 5 hours (11 hours including its active metabolite). When stopped abruptly, plasma levels drop rapidly, leaving the CNS suddenly deprived of serotonin and norepinephrine reuptake inhibition it has adapted to. The "brain zaps" or electric shock sensations are classic hallmarks of SNRI discontinuation syndrome, appearing within 1-3 days due to this short half-life. Choice A is correct because the rapid onset and characteristic symptoms directly result from venlafaxine's quick elimination from the system. Choice B describes receptor downregulation, which is a chronic adaptive change that occurs during treatment, not the acute mechanism causing withdrawal symptoms. Choice C references NMDA receptor excitotoxicity, which is irrelevant here since venlafaxine doesn't significantly interact with glutamate systems. Choice D suggests toxic metabolite accumulation, but venlafaxine's metabolites aren't toxic, and withdrawal symptoms stem from absence of the drug, not presence of harmful compounds. The key insight is that medications with shorter half-lives (like venlafaxine, paroxetine) cause more severe discontinuation syndromes than those with longer half-lives (like fluoxetine). Remember: short half-life = higher discontinuation risk. Always taper SNRIs and SSRIs gradually, especially those eliminated quickly from the body.
16. A 72-year-old patient is being treated with nortriptyline for neuropathic pain. The patient reports significant benefit but is bothered by sedation and orthostatic hypotension. Which of the following properties of nortriptyline is most likely responsible for these two specific adverse effects?
    Answer: Antagonism of alpha-1 adrenergic and H1 histaminic receptors. Orthostatic hypotension associated with TCAs is primarily due to the blockade of alpha-1 adrenergic receptors. Sedation is primarily caused by antagonism of central H1 histamine receptors. While TCAs have other actions, this option correctly links both reported side effects to their respective receptor-blocking properties. Muscarinic antagonism (A) causes dry mouth, constipation, and blurred vision. Norepinephrine reuptake inhibition (B) is part of the therapeutic effect and can sometimes cause tachycardia or hypertension. Sodium channel blockade (D) is linked to cardiotoxicity in overdose.
17. While both pregabalin and gabapentin bind to the α2-δ subunit of voltage-gated calcium channels, pregabalin exhibits certain pharmacokinetic advantages over gabapentin. Which of the following best describes a key pharmacokinetic difference that contributes to pregabalin's more predictable dose-response relationship?
    Answer: Pregabalin is absorbed via a high-capacity amino acid transporter, resulting in linear, dose-proportional absorption. Gabapentin's absorption is mediated by the L-amino acid transporter system (LAT1) in the gut, which is saturable. This leads to non-linear, dose-disproportional absorption, meaning that as the dose of gabapentin increases, the fraction absorbed decreases. In contrast, pregabalin is absorbed by a different, high-capacity transport system that does not become saturated at therapeutic doses, resulting in linear and predictable dose-proportional absorption. This predictability simplifies dosing. Neither drug undergoes significant hepatic metabolism (A) or has significant plasma protein binding (D). (B) accurately describes gabapentin's absorption, not pregabalin's.
18. A 78-year-old female with trigeminal neuralgia, a history of myocardial infarction, glaucoma, and constipation is prescribed a new medication for her facial pain. Which of the following agents would be the most problematic choice for this patient, considering all of her comorbidities?
    Answer: Amitriptyline When evaluating medications for patients with multiple comorbidities, you need to consider how each drug's side effect profile interacts with existing conditions. This question tests your ability to identify contraindications and relative risks across different drug classes used for neuropathic pain. Amitriptyline (D) is the most problematic choice because tricyclic antidepressants have significant anticholinergic effects that directly worsen this patient's conditions. The anticholinergic properties can increase intraocular pressure, potentially precipitating an acute glaucoma attack in someone with existing glaucoma. Additionally, these effects cause decreased GI motility, severely worsening constipation. Tricyclics also have cardiotoxic effects including QT prolongation and arrhythmias, which pose serious risks in a patient with prior myocardial infarction. Gabapentin (A) is generally well-tolerated with minimal drug interactions and no significant anticholinergic effects, making it safer for this patient profile. Pregabalin (B) shares gabapentin's favorable safety profile regarding anticholinergic effects and cardiac risks, though it may cause some peripheral edema. Duloxetine (C), while an antidepressant, is an SNRI rather than a tricyclic and lacks the problematic anticholinergic effects that make amitriptyline dangerous. Remember that tricyclic antidepressants have a "dirty" pharmacology profile with multiple receptor interactions beyond their intended target. When you see elderly patients with glaucoma, constipation, or cardiac conditions, immediately flag tricyclics as potentially dangerous due to their anticholinergic and cardiotoxic effects. Always consider the complete side effect profile, not just efficacy.
19. A patient experiences a witnessed generalized seizure after taking several tablets of a prescribed medication for neuropathic pain in a suicide attempt. On presentation to the emergency department, the EKG shows a QRS duration of 140 ms and a prominent R wave in lead aVR. Which medication is the most likely cause of this presentation?
    Answer: Amitriptyline The clinical presentation of seizures and characteristic EKG findings (QRS widening >100 ms, prominent R wave in aVR) is classic for a tricyclic antidepressant (TCA) overdose. The cardiotoxicity is due to blockade of fast sodium channels in the His-Purkinje system. Overdoses of gabapentin (C) and pregabalin (A) typically cause sedation, ataxia, and confusion, but are much less likely to cause life-threatening cardiotoxicity. Duloxetine (B) overdose can cause seizures and tachycardia but does not typically produce the characteristic QRS widening seen with TCAs.
20. A 68-year-old male with a history of ischemic heart disease (Q-wave abnormalities on EKG), benign prostatic hyperplasia, and painful diabetic neuropathy is being considered for pharmacotherapy. His current medications include metformin, lisinopril, and aspirin. Which of the following agents is most appropriate to avoid due to the patient's comorbidities?
    Answer: Amitriptyline Amitriptyline, a tricyclic antidepressant (TCA), should be avoided. TCAs have significant anticholinergic properties that can worsen benign prostatic hyperplasia, leading to urinary retention. Furthermore, they can cause cardiac conduction abnormalities (e.g., QT prolongation) and are relatively contraindicated in patients with pre-existing heart disease. Gabapentin (A) and pregabalin (D) lack these effects. Duloxetine (B), an SNRI, has a much lower anticholinergic and cardiotoxic potential than TCAs, making it a safer alternative in this patient.

Start this quiz